徐田锋 - 中国科学院上海药物研究所 -

个人简介

教育经历 2009.08-2014.07，中国科学院广州生物医药与健康研究院，药物化学，博士 2005.09-2009.06，山东师范大学，应用化学，学士工作经历 2019.03-至今，课题组长，研究员，中国科学院上海药物研究所 2014.11-2019.02，博士后，美国密歇根大学安娜堡校区癌症中心

研究领域

可诱导蛋白降解的小分子药物的设计与开发与肿瘤免疫相关的小分子激酶抑制剂的设计与开发

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1.Xu, S.*; Aguilar, A.*; Xu, T.*; Zheng, K.*; Huang, L.*; Stuckey, J.; Chinnaswamy, K.; Bernard, D.; Fernández-Salas, E.; Liu, L., Wang, M.; McEachern, D.; Przybranowski, S.; Foster, C.; Wang, S., Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein–Protein Interaction, Angew Chem Int Edit. 2018, 57 (6), 1601-1605. (*共同第一作者) 2.Xu, T. *; Peng, T. *; Ren, X.*; Zhang, L.; Yu, L.; Luo, J.; Zhang, Z.; Tu, Z.; Tong, L.; Huang, Z.; Lu, X.; Geng, M.; Xie, H.; Ding, J.; Ding, K., C5-substituted pyrido [2, 3-d] pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFR T790M mutant, MedChemComm. 2015, 6(9), 1693-1697. 3.Xu, T. *; Zhang, L*.; Xu, S.; Yang, C.; Luo, J.; Ding, F.; Lu, X.; Liu, Y.; Tu, Z.; Li, L.; Pei, D.; Cai, Q.; Li, H.; Ren, X.; Wang, S.; Ding, K., Pyrimido[4,5-d]pyrimidin-4(1H)-one Derivatives as Selective Inhibitors of EGFR Threonine790 to Methionine790 (T790M) Mutants, Angew Chem Int Edit. 2013, 52(32),8387-8390. 4.Han, X.; Wang, C.; Qin, C.; Xiang, W.; Fernandez-Salas, E.; Yang, C.-Y.; Wang, M.; Zhao, L.; Xu, T.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S., Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. J Med Chem. 2019, 62 (2), 941-964 . 5.Yu, L.; Huang, M.; Xu, T.; Tong, L.; Yan, X.; Zhang, Z.; Xu, Y.; Yun, C.; Xie, H.; Ding, K.; Lu, X., A structure-guided optimization of pyrido [2, 3-d] pyrimidin-7-ones as selective inhibitors of EGFR L858R/T790M mutant with improved pharmacokinetic properties, Eur J Med Chem. 2017, 126, 1107-1117. 6.Xu, S.; Xu, T.; Zhang, L.; Zhang, Z.; Luo, J.; Liu, Y.; Lu, X.; Tu, Z.; Ren, X.; Ding, K., Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties, J Med Chem. 2013, 56(21), 8803-8813.